2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171791
    WAY-166818 142629-43-4 98%
    WAY-166818 (WAY-818) is a synthetic nonsteroidal estrogen that is a selective agonist of ERβ.
    WAY-166818
  • HY-171794
    AZD1134 442548-99-4
    AZD1134 is an orally active, brain-penetrant and highly selective 5-HT1B receptor antagonist with IC50 values of 2.9 nM (human) and 0.108 nM (guinea pig), respectively. AZD1134 increases synaptic serotonin levels in guinea pigs. AZD1134 is promising for research of psychiatric disorders, such as depression and anxiety.
    AZD1134
  • HY-172101
    AChE/MAO-B-IN-7 98%
    AChE/MAO-B-IN-7 (VAV-8) is a blood-brain permeable dual inhibitor of acetylcholinesterase (AchE) and MAO-B agent. AChE/MAO-B-IN-7 can also inhibit Aβ42 aggregation for use in Alzheimer's disease (AD) research.
    AChE/MAO-B-IN-7
  • HY-172106
    TRPC5-IN-5 738603-63-9 98%
    TRPC5-IN-5 (Compound ph8) is a TRPC5 inhibitor (IC50: 1.28 μM). TRPC5-IN-5 can be used for research of neurological diseases and renal diseases.
    TRPC5-IN-5
  • HY-172121
    NMDA agonist 2 98%
    NMDA agonist 2 (compound 8d) is a potent inhibitor of NMDA receptor, with the EC50 of 0.034 μM for GluN1/2C. NMDA agonist 2 plays an important role in neurological and psychiatric disorders.
    NMDA agonist 2
  • HY-172127
    NUAK1-IN-1 98%
    NUAK1-IN-1 (Compound 9) is a NUAK1 (IC50 of 5.012 nM) and CDK4 inhibitor. NUAK1-IN-1 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research.
    NUAK1-IN-1
  • HY-172128
    NUAK1-IN-2 98%
    NUAK1-IN-2 (Compound 24) is a NUAK1 (IC50 of 3.162 nM) and CDK2/4/6 inhibitor. NUAK1-IN-2 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research.
    NUAK1-IN-2
  • HY-172129
    HDAC6-IN-52 2636786-68-8 98%
    HDAC6-IN-52 (EX.1) is a potent inhibitor of HDAC6, with the inhibitory rate of 100% at 10 μM. HDAC6-IN-52 plays an important role in central nervous system diseases including neurodegenerative diseases such as Alzheimer’s disease andprogressive supranuclear palsy.
    HDAC6-IN-52
  • HY-172140
    Ebio3 98%
    Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. Ebio3 binds to the KCNQ2 channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy.
    Ebio3
  • HY-172143
    ATUX-8385 2088956-86-7 98%
    ATUX-8385 is a potent PP2A activator. ATUX-8385 binds to PR65 subunit. ATUX-8385 has the potential for the research of cancers and chronic conditions such as Alzheimer’s disease and chronic obstructive pulmonary disease.
    ATUX-8385
  • HY-172147
    SSTR4 agonist 5 2761347-44-6 98%
    SSTR4 agonist 5 (Compound 5) is the orally active agonist for somatostatin receptor 4 (SSTR4) with an EC50 of 0.228 nM. SSTR4 agonist 5 exhibits good stability in human/rat liver microsomes. SSTR4 agonist 5 inhibits mechanical hyperalgesia in rat models.
    SSTR4 agonist 5
  • HY-172152
    MP-010 3024617-59-9 98%
    MP-010 is a FKBP12 ligand that regulates cytosolic calcium by stabilizing RyR channel activity. MP-010 promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice, as evidenced by improved motor coordination, increased integrity of neuromuscular junctions, and significantly enhanced survival of spinal motor neurons. MP-010 can be used for research in the field of neurological diseases.
    MP-010
  • HY-172176
    RA-PR058 98%
    RA-PR058 is an orally active Ramalin derivative with blood-brain barrier permeability, exhibiting multi-target regulatory effects and favorable pharmacokinetic properties. RA-PR058 demonstrates potential as a multi-target modulator for Alzheimer's disease by reducing the expression of BACE1, tau protein hyperphosphorylation, and anxiety-like behaviors.
    RA-PR058
  • HY-172198
    GSK3-IN-10 844441-56-1 98%
    GSK3-IN-10 (Compound 4) is a multi-target inhibitor, that mainly targets GSK3α and GSK3β with IC50 of 1.0 nM and 2.0 nM. GSK3-IN-10 inhibits the activation of β-catenin, promotes the neuronal survival, and exhibits a protective effect against endoplasmic reticulum stress.
    GSK3-IN-10
  • HY-172213
    (3S,6R)-NML 1585965-04-3 98%
    (3S,6R)-NML is a NMDA receptor antagonist, with pIC50s of 4.8 (GluN1-GluN2A), 4.6 (GluN1-GluN2B), 5.0 (GluN1-GluN2C), 5.0 (GluN1-GluN2D) respectively. (3S,6R)-NML can be used for depression research.
    (3S,6R)-NML
  • HY-172219
    CUR-IPA 98%
    CUR-IPA is a cholinesterase inhibitor, with IC50 of 5.99, 59.30, and 60.66 μM for eAChE (electric eel), hAChE (human), and hBChE (human), respectively. CUR-IPA can scavenge free radicals and has antioxidant activity. CUR-IPA can be used in the research of cognitive dysfunction.
    CUR-IPA
  • HY-172232
    STG-001 1911650-53-7 98%
    STG-001 is a retinol binding protein 4 (RBP4) antagonist. STG-001 inhibits RBP4 to reduce the synthesis of retinal and diretinol, thereby preventing photoreceptor degeneration. STG-001 can be used in the study of sexually precocious nephropathy (STGD).
    STG-001
  • HY-172246
    Zilvetrigine 3002072-52-5 98%
    Zilvetrigine is a sodium channel blocker. Zilvetrigine can be used as analgesics.
    Zilvetrigine
  • HY-172261
    YY-23 1365029-75-9 98%
    YY-23 is a selective inhibitor of NMDAR (containing GluN2C or GluN2D). YY-23 inhibits GABAergic neurotransmission and enhances excitatory transmission by inhibiting NMDARs containing GluN2D on GABAergic interneurons in the prefrontal cortex. YY-23 has antidepressant activity and can be used for the research of neurological diseases.
    YY-23
  • HY-172277
    DSPE-PEG1000-R9 98%
    DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery.
    DSPE-PEG1000-R9
Cat. No. Product Name / Synonyms Application Reactivity